Literature DB >> 17643768

Tissue inhibitor of metalloproteinase 2 and coronary artery lesions in Kawasaki disease.

Kenji Furuno1, Hidetoshi Takada, Ken Yamamoto, Kazuyuki Ikeda, Takuro Ohno, Vahid Khajoee, Yumi Mizuno, Toshiro Hara.   

Abstract

OBJECTIVE: To identify cytokine genes uniquely expressed in peripheral blood mononuclear cells (PBMNCs) in the acute phase of Kawasaki disease (KD) with coronary artery lesions (CALs). STUDY
DESIGN: We screened the mRNA expression levels of PBMNCs from 4 pairs of KD patients with and without CAL using DNA microarray. The result was confirmed by real-time polymerase chain reaction (RT-PCR). The genetic association study was performed to analyze the significance of single nucleotide polymorphisms in the identified gene for the development of CAL in KD patients (184 controls, 144 KD patients with CAL, 64 KD patients without CAL).
RESULTS: The microarray analysis showed that tissue inhibitor of metalloproteinases 2 (TIMP2) was expressed at higher levels in PBMNCs of KD patients with CAL than in KD patients without CAL. Quantitative RT-PCR confirmed that the expression levels were significantly higher in the KD patients with CAL than in those without CAL (P < .05). Among KD patients, TIMP2 promoter polymorphisms were significantly associated with a risk of CAL (P < .01). There was a significant difference in the transcriptional activities between the haplotypes of the TIMP2 promoter polymorphisms by reporter assay using U-937.
CONCLUSIONS: TIMP2 overexpression and the promoter polymorphisms might play a role in the development of CALs.

Entities:  

Mesh:

Substances:

Year:  2007        PMID: 17643768     DOI: 10.1016/j.jpeds.2007.03.010

Source DB:  PubMed          Journal:  J Pediatr        ISSN: 0022-3476            Impact factor:   4.406


  5 in total

Review 1.  Genetic polymorphisms in Kawasaki disease.

Authors:  Ho-chang Kuo; Wei-chiao Chang
Journal:  Acta Pharmacol Sin       Date:  2011-09-05       Impact factor: 6.150

2.  TIMP2 gene polymorphisms are associated with hypertension in patients with myocardial infarction.

Authors:  José Manuel Rodríguez-Pérez; Nancy Martínez-Rodríguez; Gilberto Vargas-Alarcón; Maite Vallejo; Irma Eloisa Monroy-Muñoz; Carlos Posadas-Romero; Eric Kimura-Hayama; Teresa Juárez-Cedillo; José Manuel Fragoso; Nonanzit Pérez-Hernández
Journal:  J Genet       Date:  2014-08       Impact factor: 1.166

3.  Transcript abundance patterns in Kawasaki disease patients with intravenous immunoglobulin resistance.

Authors:  Wen Fury; Adriana H Tremoulet; Virginia E Watson; Brookie M Best; Chisato Shimizu; Jennifer Hamilton; John T Kanegaye; Yi Wei; Chiayi Kao; Scott Mellis; Calvin Lin; Jane C Burns
Journal:  Hum Immunol       Date:  2010-06-20       Impact factor: 2.850

Review 4.  The role of infection in Kawasaki syndrome.

Authors:  Nicola Principi; Donato Rigante; Susanna Esposito
Journal:  J Infect       Date:  2013-04-18       Impact factor: 6.072

Review 5.  Understanding the pathogenesis of Kawasaki disease by network and pathway analysis.

Authors:  Yu-wen Lv; Jing Wang; Ling Sun; Jian-min Zhang; Lei Cao; Yue-yue Ding; Ye Chen; Ji-juan Dou; Jie Huang; Yi-fei Tang; Wen-tao Wu; Wei-rong Cui; Hai-tao Lv
Journal:  Comput Math Methods Med       Date:  2013-03-06       Impact factor: 2.238

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.